TGM3 rs6082527: Understanding Pharmacogenomic Associations
The rs6082527 variant is a single nucleotide polymorphism located in the TGM3 gene. Research has identified this variant as being significantly associated with variations in multi-gene expression profiles and cellular sensitivity to the chemotherapy drug gemcitabine.
What each genotype means
Typical gemcitabine response profile
This genotype represents the major allele configuration for this variant. Research has associated the TGM3 region with variations in gemcitabine cytotoxicity, though the clinical impact of this specific genotype remains a subject of ongoing study. Please discuss any concerns regarding medication response or dosing with your clinician or pharmacist.
This is the most common genotype observed across most global populations.
Intermediate gemcitabine response profile
Carrying one copy of the minor allele may influence the expression of genes associated with gemcitabine sensitivity. While this variant has been linked to drug response in research settings, it is not currently used to guide clinical dosing. Always consult with your healthcare provider regarding your specific treatment plan.
This heterozygous genotype is found at varying frequencies depending on ancestral background, appearing in a significant minority of individuals.
Altered gemcitabine response profile
This genotype involves two copies of the minor allele, which has been statistically associated with differences in gemcitabine cytotoxicity and multi-gene expression profiles in research studies. These findings are based on laboratory models and require clinical validation before they can be used for medical decision-making. Please discuss your medication options and any potential side effects with your doctor.
This genotype is less common than the AA or AG configurations and shows significant variability across different ethnic populations.
What is rs6082527 and Where is it Located?
The variant rs6082527 is a specific change in the DNA sequence located within the TGM3 gene. In genomics, a single nucleotide polymorphism (SNP) like rs6082527 represents a position where one of the four DNA building blocks—adenine, thymine, cytosine, or guanine—differs between individuals. This particular SNP is situated in the 5'-flanking region of the TGM3 gene. The 5'-flanking region is a segment of DNA located upstream of the gene's coding sequence, which often contains regulatory elements that control when and how much of a protein is produced. Because of its location, researchers investigate whether this variant influences the expression levels of the TGM3 gene, potentially altering the amount of transglutaminase 3 enzyme available in the cell.
The Role of the TGM3 Gene
The TGM3 gene provides the instructions for creating the transglutaminase 3 enzyme. This enzyme is a member of the transglutaminase family, which functions by cross-linking structural proteins. In the human body, TGM3 is essential for the formation of the cornified envelope, a tough, protective barrier found in the outer layers of the skin and hair follicles. By linking proteins together, the enzyme helps maintain the structural integrity of these tissues. Beyond its role in skin and hair, TGM3 is also being studied for its potential role as a tumor suppressor in various cancers. Research suggests that changes in TGM3 expression or function may influence cellular pathways related to cell growth and differentiation, which is why it is a subject of interest in oncology and pharmacogenomics.
Research Associations and Evidence Strength
The association between rs6082527 and gemcitabine response is categorized as having moderate evidence. A notable study published in 2009 identified that this SNP was significantly associated with both multi-gene expression profiles and the IC50 of gemcitabine, which is a measure of the drug's potency in inhibiting cell growth. To validate these findings, researchers performed siRNA knockdown experiments in tumor cell lines, which confirmed that altering the expression of genes associated with this SNP changed the cells' sensitivity to gemcitabine. While these findings provide a functional link between the variant and drug response in laboratory settings, it is important to note that this evidence is based on cell-based models. Further clinical studies are required to determine how these findings translate to individual patient outcomes in a real-world medical setting.
Population Frequency and Variability
The frequency of the rs6082527 variant is known to be variable across different human populations. Genetic variants in drug-related genes often show distinct patterns of distribution depending on geographic ancestry. Because human populations have different genetic histories, the prevalence of specific alleles can differ significantly between groups of African, Asian, European, and other ancestries. While specific global frequency percentages for rs6082527 may fluctuate in large-scale databases, the general principle in pharmacogenomics is that the impact of a variant can be highly dependent on an individual's ancestral background. Researchers emphasize that understanding these population-specific differences is crucial for the future of personalized medicine, as it helps explain why individuals may respond differently to the same therapeutic interventions.
What You Can and Cannot Do With This Information
It is vital to understand that information regarding rs6082527 is intended for educational purposes and does not constitute medical advice. You cannot use this information to diagnose a condition, predict your personal response to chemotherapy, or make any decisions regarding your medical treatment. Pharmacogenomic research is complex, and drug response is influenced by a multitude of factors, including other genetic variants, environmental influences, and overall health status. If you are undergoing treatment with gemcitabine or any other medication, you should never alter your dosage or treatment plan based on genetic data without consulting your healthcare provider. Always discuss your genetic information and any concerns about your medication with your clinician or a qualified pharmacist, who can provide guidance based on your specific clinical context.
How common is this variant?
The frequency of the rs6082527 variant is variable across different global populations, reflecting the diverse genetic architecture of human ancestries.
Frequently asked questions
What is the TGM3 gene?
The TGM3 gene encodes the transglutaminase 3 enzyme, which is responsible for cross-linking proteins to maintain the structural integrity of skin and hair. It is also being studied for its potential role in cancer biology.
Is rs6082527 used to guide gemcitabine treatment?
No, rs6082527 is not currently used in routine clinical practice to guide gemcitabine dosing. While research has shown an association in laboratory studies, it has not been established as a standard clinical biomarker.
Can I use a genetic test to see if I have this variant?
While some direct-to-consumer genetic tests may report on various SNPs, this variant is not typically included in standard clinical pharmacogenomic panels. Always consult a doctor before seeking genetic testing for medical purposes.
What should I do if I am concerned about my response to chemotherapy?
If you are concerned about your response to chemotherapy, you should speak directly with your oncologist. They are the best resource to discuss your treatment plan, potential side effects, and any relevant clinical testing.
Sources & further reading
Educational information only, last refreshed 10/14/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs6082527?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29